Pharma Resisting Efforts To Send Drug Pricing Savings To US Budget ‘Black Hole’ – Pfizer’s Bourla

Biopharma draws a line in the sand on drug pricing reform and offers to come to the table, but given the fracturing support for Rx legislation within the Democratic caucus, industry may not have as much need to negotiate with Congress. More detail on industry’s latest proposals for lowering costs may come in the second half.